Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial
Authors' conclusion
Among patients with critical COVID-19, 12 mg vs. 6 mg dexamethasone daily did not result in a statistically significant difference in the composite outcome of death or thromboembolism.
Study context
- Population
- Swedish and Danish ICU patients with critical COVID-19 enrolled in the COVID STEROID 2 trial
- Participants
- 357 participants
- Comparison
- Dexamethasone 12 mg vs 6 mg daily for up to 10 days
- Primary endpoint
- Composite of:
- Death
- Thromboembolism during intensive care
- Follow-up
- During intensive care
Methodological detailsblinded
- Blinded
Primary result
As reported in the abstract
Each group vs 6 mgAdjusted odds ratio (95% CI)P value
12 mg
0.93(0.58–1.49)
P = 0.77- 12 mg
- unadjusted absolute risk difference - 0.5% (95% CI - 10 to 9.5%); P = 1.00
Secondary outcomes
Thromboembolism, major bleeding and any bleeding during intensive care
- No firm evidence of differences in any of the secondary outcomes
Original publication
Effects of 12 mg vs. 6 mg dexamethasone on thromboembolism and bleeding in patients with critical COVID-19 - a post hoc analysis of the randomized, blinded COVID STEROID 2 trial. Ann Intensive Care. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →